AOD9604 is a modified version of the hGH fragment 176-191 peptide (contains a di-sulfide bridge) and thus a derivative of human growth hormone (hGH). Originally developed as a lipolytic (fat burning) compound, AOD9604 has shown benefit in studies of heart disease, osteoarthritis/cartilage repair, and metabolic syndrome. AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis in animal studies.
Anti-Obesity Drug Fragment for Metabolic Research
AOD-9604 is a modified fragment of human growth hormone (hGH) specifically designed for research into metabolic pathways and adipose tissue regulation. This peptide retains the fat-reducing properties of hGH while eliminating growth-promoting effects, making it valuable for targeted metabolic studies.
Research Applications:
- Lipolysis pathway investigation
- Adipose tissue metabolism studies
- Growth hormone receptor research
- Metabolic regulation mechanism analysis
- Fat oxidation pathway studies
Product Characteristics:
- C-terminal fragment of hGH (176-191)
- Modified amino acid sequence
- Enhanced stability profile
- Suitable for metabolic research protocols
For laboratory research use only.
AOD-9604 6mg - Growth Hormone Fragment Research Peptide
- Typical dosages can range, but commonly it’s 2mg per vial, which can be reconstituted with sterile water.
- The peptide is typically administered via subcutaneous injection.
- The dosing regimen often involves one injection per week, as it has a prolonged half-life (due to the DAC component).
- As with any peptide, there could be risks, such as injection site reactions, water retention, or possible changes in insulin sensitivity.
- It’s important to monitor health regularly and consult with a healthcare provider, especially if using for long-term purposes.
